The medical research community on BrightTALK brings together medical and research professionals. Find relevant webinars on medical research, laboratory science, continuing medical education and more presented by recognized medical researchers. Join the conversation by participating in live webinars and round table discussions on the latest in medical devices, medical research practices and trends in the healthcare industry.
Join us for an interactive webinar with Dylan O. Adams, a Senior Patent Attorney and Amazon Bestselling Author of "Patents Demystified: An Insider's Guide to Protecting Ideas and Inventions."
His book, Patents Demystified, is the Official Patent Guide of The American Bar Association and is used at Top Universities Including Harvard and Stanford. As a senior patent attorney, Dylan has experience with U.S. and foreign patents in a wide variety of technology fields, including software, computer hardware and biotechnology.
In this webinar, we will explore which patent protection strategy best fits your business goals, both short and long-term. We will discuss best practices on how to work with your patent attorneys to craft the strategy that fits current and future budget constraints, and how you can easily leverage your patent assets and derive the most value from them.
Welcome to PatSnap. In this initial onboarding webinar, emphasis will be put on understanding the core aspects of intellectual property and applying this to the fundamental tools and features within our system.
You’ll leave these sessions understanding how to:
•Perform basic searches on PatSnap, using IPC’s and boolean operators
• How to filter your search results to ensure only the most relevant patents appear
• Customising your account settings
• Identify individual sections of a patent document, (patent families, citation analysis etc...)
• Utilise your research efforts by saving and sharing your work, building basic lists, or downloading full patent documents.
Join us as we discuss CiteScore metrics - the free, transparent, comprehensive, and current metrics now available as part of the Scopus basket of metrics.
Here are some of the topics you can expect to learn about:
-The Scopus basket of metrics
-Why have CiteScore metrics been added to the basket?
-What are CiteScore metrics?
-How can CiteScore metrics be accessed?
-How you can get involved in defining the basket of metrics
In this webinar, Dr. Michael Samoszuk will discuss the correlation between images of urine sediment particles captured on the iRICELL3000 and images viewed manually under the microscope using actual patient samples. Attendees will learn how these images compare and how automated microscopy helps to reduce user subjectivity in microscopy by standardizing the process.
Join Laura Schoppe, President of Fuentek, a consulting firm specializing in IP asset management, tech transfer and commercialization - on Wednesday 11th January to find out how you can improve the ROI of your intellectual property by using patent data.
In this session, you will learn how to get early market feedback, and develop new commercial opportunities for your IP. Laura will provide practical, actionable advice on:
- Readiness Assessment for Market Planning (RAMP)
- Identifying potential collaborators and licensees
- Verifying market fit and collecting feedback
- Developing a licensing / commercialization strategy for your IP
There will also be time for a live Q&A, so if you have any questions about commercializing your IP, this is a great opportunity to speak to an expert.
What does the Apple vs Samsung SCOTUS ruling mean for the patent industry in 2017?
Gene Quinn and special guests look back at the most important moments of 2016, and consider the issues that look set to shape the patent industry in 2017
It is that time once again when we look back on the previous year in preparation to close the final chapter on 2016, and we begin to look ahead and ask what is in store for the new year.
Gene Quinn, patent attorney and founder of IPWatchdog.com, will moderate this discussion, alongside a panel of very special guests.
Join us as we discuss:
2016: The Year of the Patent Trial and Appeal Board – From the Supreme Court deciding Cuozzo, to the Federal Circuit spending much of the year rubber stamping the PTAB, it has been a rollercoaster year.
2016: Software Patents Strike Back – A series of Federal Circuit decisions post-Alice have started to provide meaningful insight into how software can be described so that it will be considered patent eligible.
2017: Regulatory Reform NOT Patent Reform – Patent reform will almost certainly not be a top priority for the Trump Administration, but regulatory reforms to the PTAB could be seen and may be quite significant and beneficial to patent owners.
2017: Supreme Court to Decide Samsung v. Apple - The decision will either validate the value of design patents or make design patents virtually worthless.
Resource constraints, financial and human, mean that most universities simply do not have the luxury of being able to back every research commercialisation opportunity. Therefore, it is essential to develop a strategy and process that optimises the chances of backing winners, be it to maximise the financial return or to address the non-financial impact agenda.
PatSnap will be teaming up Isis Enterprise, the innovation consultancy division of Oxford University Innovation, to discuss some key measures that can be taken to identify promising commercialisation projects that are underpinned by strong intellectual property. We will also be providing insight on methods for trimming and shaping academic patent portfolios so that they are optimised for strong overall returns.
In this webinar, Dr. Guido Vranken and product manager Lobke Tremmerie discuss how to implement Bulls XB algorithm, which uses RBC indices to create a weighted moving average of patient sample results, to statistically monitor hematology results. This unique algorithm, offered on Beckman Coulter hematology instruments, allows users to monitor result quality with no additional reagents, software licenses or costs. Laboratories worldwide can implement this simple, powerful tool to enhance results and improve compliance. P.A.C.E. credit is available for your participation.*
Dr. Guido Vranken has been working with customers for over 30 years across different disciplines, including protein chemistry, immunoassay and hematology. He specializes in conducting internal and external validation studies. Dr. Vranken spent three years as a lecturer on statistics at the University of Ghent.
Lobke Tremmerie earned her environmental engineering degree from the University of Ghent in 2002. She first became an electrophoresis and nephelometry sales engineer at Analis, Beckman Coulter’s exclusive Belgian distributor. Following her true passion, she transferred into the hematology division in 2004. Ms. Tremmerie currently serves as Analis’ cellular biology product marketing manager.
The atomic force microscope (AFM) has played an essential role in 2D materials research since it was used to confirm the first isolation of graphene. Today’s AFMs are even more powerful, with higher spatial resolution, faster imaging rates, greater environmental control and enhanced modes for mapping physical properties. They can image crystal lattice structure as well as nanoscale morphology, and sense local electrical, mechanical and functional response in more ways than ever before.
In this webinar we explore the latest AFM tools that enable higher resolution, sensitivity and more quantitative results for analysing 2D materials. We’ll present results from measurements of a variety of 2D materials for device manufacturing, energy storage and optoelectronics including:
• MoS2 and graphene;
• measurements of mechanical properties;
• kelvin probe imaging (KPFM) of operating transistors;
• electromechanical measurements.
Finally, we discuss how AFM can now be used to accurately determine the thickness of single or multiple layers of a 2D material. This will challenge the misconception that AFM cannot be used to precisely measure the thickness of 2D materials.
In the third of our webinars showcasing presentations from the PMB 60th Anniversary Symposium, Bas Raaymakers examines the use of image guidance during radiation therapy. He will describe the various options available for radiotherapy guidance, including in-room CT-on-rails, MV imaging, fluoroscopy, ultrasound, tracking of implanted beacons and cone-beam CT. In particular, he will discuss the use of MRI for real-time visualization of the tumour and its surroundings during treatment.
With rising healthcare costs, more informed and engaged patients, and advancing technology, health wearables have seen a significant uptake in recent years. However, the full potential of health wearables has yet to be recognised and there are still challenges to be resolved. What needs to be done on the regulatory, technical and healthcare side to take health wearables to the next level?
In this webinar, experts from the life sciences and technology industries discuss their views on the current state and future developments of health wearables, including:
– The user perspective: perception, adoption and expectations today and tomorrow
– The technology perspective: biggest successes and most room for improvements
– The societal and regulatory perspective: cost and risks versus benefits and opportunities
In this webinar, Dr. Michael Samoszuk discusses the correlative relationships between urine chemistry analytes and the particles noted under the microscope. Attendees will learn how using the knowledge of these correlations can optimize parameter setting for improved laboratory workflow.
This webinar addresses practical computational issues in discrete calculations of the path of charged or multipole particles in electric and magnetic fields.
We begin by showing the theory and an Excel macro implementation of some standard ODE time-based solvers as applied to the charged-particle case. We also discuss potential benefits of a nonstandard distance-based solver configuration.
Next some examples are provided to illustrate trade-offs between the number of calculations and the accuracy of the result according to various criteria. For example, depending on one’s needs, the simulation set-up might produce output that is either a dense set of (x, y, z) points that plot as a smooth curve, or a much sparser set of points that are individually more accurate than the dense set.
The webinar will end by examining what can be done with the data obtained. Calculations based on a linear interpolation between points are straightforward, but may force one to use an inefficient ODE set-up. This can take excessive computation resources, hence a longer time than necessary to produce accurate results. Some alternatives will be demonstrated using various degrees of physical insight to get the most information possible from the given ODE output data.
Learn how Jocelyn Kolb-Dewitt and Darlene Farris-LaBar, co-directors of the G3D Stratasys Super Lab at East Stroudsburg University, inspire and empower students in art and design with 3D printing. Darlene Farris-Labar designs and 3D prints plants and flowers to reimagine an ecosystem on the brink of extinction. Explore product design with Jocelyn Kolb, who 15 years ago implemented 3D printing into her art and teaching. Analyze and understand how young minds interface software and hands-on learning for increased retention. Assess the impact of real-world projects including robotic prosthetics, DICOM scans, clothing design, biological models and artistic representations of microscopic life forms.
Join us and PHOENIX group as we delve into the concept of current launch excellence and the role of patient insights in overcoming the multiple challenges the industry currently faces.
Key topics to be discussed include:
– The challenges of launching a product in Europe
– How pharma can improve its understanding of the process through the use of business intelligence
– How insights from new data can be applied to the process of launch excellence
– The role of real-world data in launch strategy
– The downstream effect of applying real-world data to product launch on patient outcomes.
Dr. Rybicki is Professor and Chair of Radiology at the University of Ottawa and Chief of Medical Imaging at The Ottawa Hospital. In this webinar, you’ll examine the role of 3D printing in medicine and hospitals. Learn about use cases and different models for hospital-based 3D printing including facial transplants, surgical guides, radiology and standard research tools. Dr. Rybicki illuminates current trends and future direction in 3D printing while addressing parallel topics such as costs, education, printer selection and achieving objectives.
Working with QuintilesIMS, we present a digital debate which will offer modellling-based insights into the future of hepatitis C treatment.
Key topics to be discussed include:
– The burden of HCV
– The current market landscape
– The current patient access model and its impact on budget
– Cost efficiencies shown by modelling
– Cure versus lifetime treatment costs
To celebrate the 30th anniversary of the Nobel prize in scanning tunnelling microscopy (STM) and the 30th anniversary since the first paper in atomic force microscopy (AFM), Nanotechnology™ has been organising a focus collection with guest editors Franz Giessibl, Rodolfo Miranda and Johannes Barthes to collate some of the latest cutting-edge progress developing and exploiting these scanning probe techniques.
In this webinar, we invite one of the guest editors of the collection, members of our editorial board and authors of contributions in the collection itself to join our panel to look at some of the highlights in STM and AFM over the past 30 years and some of the most exciting research developments in the field today.
Immuno-oncology therapies that harness the body’s own defences to fight tumours are widely acknowledged as the new frontier in cancer treatment, but until recently only a few products had reached the market for a limited number of indications.
Over the past 12 months several new products have been approved for a wider range of tumour types and with pipelines boasting numerous other products in the area, competition looks set to hot up.
On November 17 Research Partnership, in association with PMGroup, will host a free webinar which will explore the key features of the immuno-oncology market and the critical success factors for remaining competitive.
I would like to invite you to register for the webinar - either to watch it live on the day or for access to a recorded version.
In this webinar, Dr. Michael Samoszuk will discuss how red blood cell data reported from urine chemistry test strip analysis can correlate to red blood cell data gathered from the microscope, even when the data appears to be conflicting. Attendees will discover some of the underlying factors that could cause this to occur and learn how to minimize reporting inconclusive or inaccurate results.
The CRISPR/Cas genome editing system has revolutionized almost every aspect of the life science industry. Until recently, the most used formats for this technology have been plasmids, mRNA, or lentivirus. Each reagent has been successful in its own right, however, each approach has limitations. SygRNATM, the two-part synthetic crRNA and tracrRNA, increases the pace of research, decreases costs, and can be used with Cas9 protein, Cas9 mRNA and Cas9 expressing cells/models.
This webinar discusses the development of the SygRNATM system, protocol optimization, and proposes workflows that enable scientists to quickly incorporate CRISPR technologies into their research.
Over the past 20 years, behavioural economics has identified factors that influence and determine how people behave, including alternative decision-making pathways and many cognitive biases and heuristics. Taking account of these helps to build a clear view of how healthcare customers think and behave in relation to your product in the real world.
This short masterclass explores ‘quantitative demand assessment research’ – what it is and how insights from behavioural economics can improve the application of this important tool in pharmaceutical market research.
The masterclass will:
•Introduce demand assessment research and why it is important to healthcare market research
•Discuss how insights from behavioural economics can improve quantitative demand assessment market research
•Highlight a range of techniques using behavioural economics that help you build a more accurate picture of your customers and market.
This webinar aims to highlight the benefits of correlative Raman imaging for the analysis of chemical composition, crystallinity, stress and optoelectronic properties of materials such as semiconductors, 2D materials and electrodes. Used in combination with either atomic force microscopy or scanning electron microscopy, Raman correlative microscopy provides deep insight into the relation between molecular and structural features of materials – even in 3D.
The principles of state-of-the-art confocal Raman imaging will first be introduced, then its power as an ideal tool for investigating the chemical and molecular characteristics of a sample will be demonstrated with examples of 2D materials, semiconductors and battery electrodes. The webinar will describe clearly the advantages and ease- of- use offered by Raman imaging systems integrated with other microscopy technologies.
H&E is the most frequently used stain in histology and is the basis for diagnostics and further selected methods. Thus it is important to have brilliant staining. We will show which minor factors can give a negative effect or spoil the result completely. Tips will be given on improving the sensitivity of the stain. For PAS, we will give advice on how to avoid common errors and always get colourful results.
We will discuss:
•How to prevent "critical situations"
Optical devices are key components in many areas, such as communications, remote sensing and medical applications, and their role will increase in the future. Simulations are already a very efficient way of optimizing a device, even before the prototype stage. However, simulating optical devices needs distinct consideration due to the special material models, such as graphene, or simply due to the size of the device in relation to the wavelengths of interest.
CST STUDIO SUITE® offers a unique platform for handling such challenges. The user may import or build even highly complex structures using a user-friendly, interactive GUI. The photonic/plasmonic behaviour of the device can then be simulated by selecting the most appropriate algorithm (e.g. FIT/FDTD, FEM, BEM/MoM, MLFMM and more). Dispersive, anisotropic and nonlinear materials are supported. High-performance computing (HPC) options, such as MPI or GPU, are available, and the results can be displayed and analysed in the GUI using a comprehensive post-processing library and state-of-the-art visualization engine.
In addition, CST STUDIO SUITE® includes multiphysics solvers linked to EM, allowing users to, for example, simulate the effect of thermal tuning.
This webinar will demonstrate how CST STUDIO SUITE can be used to analyse a number of essential optical devices, such as silicon-on-insulator (SOI) waveguide components, photonic crystals (PC), plasmonic devices and optical gratings.
Everyone in pharma is talking about patient centricity, but how is the drive received ‘on the ground’ among patients who are its focus? How is it unfolding and how far is it being implemented? Do patients even notice it is happening?
On the 24 January, Cello Health Insight in association with PMGroup, will host a free webinar which will look to unravel the multi-faceted issue of patient centricity from the patient perspective.
What does it really mean for patients and how are they befitting from the initiative? What can market research contribute to our understanding of the current state of play of patient centricity?
It is time to take stock and ask ourselves whether the patient-focused activities are benefiting patients and influencing R&D or are they simply a marketing initiative.
Three-dimensional cell cultures, and multicellular tumor spheroids in (MCTS) in particular, have recently become a widely used tool for preclinical anticancer drug testing in high-throughput screening (HTS) setup. However, even though MCTS have been applied for HTS, their use has been limited to simple assays, such as assessing cell viability or inhibition of growth.
This webinar will cover new approaches to MCTS-based HTS. It will present a new, robust viability assay, well-suited for HTS and based on green fluorescent protein (GFP) used as a surrogate marker of spheroid viability. It will also review a first-ever approach to obtain information-rich transcriptomic data from drug-treated MCTS on a large scale. In addition, the presenter will demonstrate how this novel platform resulted in the identification of previously unrecognized, context-dependent drug responses of cancer cells and in findings with potential clinical relevance.
In summary, this webinar will demonstrate new ways of how MCTS-based HTS can be used to provide unique insights into context-dependent biology and cellular drug responses.
About the Presenter:
Wojciech Senkowski will soon complete his Ph.D. in Medical Sciences at Uppsala University, Sweden. In his work, he looks for applications of various tumor spheroid models in high throughput drug screening. For his work, Wojciech has received the AACR Scholar-in-Training Award. He was also a presenter and expert panelist at the Genetic Engineering & Biotechnology News webinar on 3D cell cultures, sponsored by Corning in February of 2016.
The healthcare industry is undergoing rapid transformation. By 2025, the healthcare ecosystem is expected to look drastically different from today. In 2025, global trends of aging populations, rising chronic disease prevalence and urbanization are bound to further strain healthcare systems already grappling with issues of healthcare access, quality, and cost. In response, new business models are expected to emerge to address the needs of the future. In order to make the most gains, stakeholders must successfully leverage this transformation.
This webinar will take a look at the various ways in which you can utilize the plethora of tools in the PatSnap armory to make sure you’re up to date on your competitors, suppliers, and even your own portfolio.
Whether it’s making sure you know about the new patents that have been filed, or the new markets that have been identified, we can help ensure you’re not behind on the news.
Over the past decade, the adoption of digital solutions has increased significantly throughout the healthcare industry. This exceptionally strong growth trajectory is expected to continue into the foreseeable future as U.S. healthcare organizations transform to meet the demand for more efficient, clinically integrated and decentralized care systems that serve empowered, technologically-savvy consumers who strongly value convenience and personalization.
Continuous bioprocessing offers potential to enhance productivity and product quality uniformity while simultaneously decreasing facility footprint and associated operational overhead. Advances in technology and increasing commercial pressures are leading to an increased interest in continuous processing across the biopharmaceutical sector. A number of companies are exploring and advancing continuous bioprocessing and this presents a range of opportunity and challenges, including the use of Process Analytical Technology (PAT) for process characterization, process control, and process robustness, in support of a Rapid Product Release (RPR) strategy.
Sourcing for the manufacture and control of Antibody-Drug Conjugates (ADCs) used in clinical trials requires strategic planning, establishment of a specialized support network, and execution of several interdependent tasks. ADCs are complex molecules, a fusion of a biological, the monoclonal antibody (mAb), and of small molecules, the linker and the toxic payload. Facilities of acceptable standards for the handling of high potency materials need to be engaged, and there is a limited supply currently. This is further complicated by the fact that there is not one contract facility that has fully integrated services, a “one-stop shop” capable of mAb production, linker and/or payload synthesis, conjugation of mAb to linker-payload to make the Drug Substance, and finally, formulation of the ADC to make the Drug Product. Strategizing the best outsourcing practices for producing and testing ADCs, and establishing guiding principles for externalization to ensure the selection of the right CMOs for ADC outsourcing and technology transfer, will be further discussed.
Almost all clinics, small and large, use magnetic resonance images (MRI) in their treatment-planning workflows. Modern treatment planning requires images of high geometric fidelity with high spatial and contrast resolution to delineate disease extent and proximity to adjacent organs at risk. However, imaging protocols needed for accurate treatment planning differ significantly from those used in diagnostic radiology. As the integration of MRI into radiation oncology is expanding rapidly, a need exists to highlight the considerations for safe and effective implementation. This webinar will describe the major differences from diagnostic MRI, provide an overview of MRI safety and training models, introduce clinical-workflow considerations, and describe the development of a robust quality-assurance programme. Special considerations for motion management and treatment planning will be described.
In our webinar, Identifying Men with Significant Prostate Cancer—The Role of phi and Other Biomarkers, Dr. E. David Crawford will discuss key issues that challenge a physician's ability to make informed decisions regarding whom to biopsy for prostate cancer. After the webinar, you will be able to:
• Understand the historical perspective and controversy regarding prostate-specific antigen (PSA) screening
• Improve your interpretation of a PSA result
• Use biomarkers, such as Prostate Health Index (phi), to reduce negative biopsies and have more confidence in the decision to biopsy
• Understand how the phi score, combined with family and patient history, can determine patient management decisions
Dr. Crawford is an internationally renowned urologist and distinguished endowed professor of surgery, urology and radiation oncology. He also serves as the head of the section of urologic oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles.
In the fourth of our series of webinars showcasing presentations from the PMB 60th Anniversary Symposium, Katia Parodi examines the key ingredients of modern adaptive radiotherapy, including fast computational models and methods for in-vivo dose/range assessment. She also takes a look forward to the era of biological guidance.
Observable foreign and particulate matter has for a long time been recognized as a critical quality attribute for production of injectable protein formulations. Recently, a focus shift towards these particles and even smaller particles (particulate matter or subvisible particles) has been seen from the pharmaceutical industry, academia and the different regulatory bodies. Two of the central documents in this context are:
1. The FDA Guidance for Industry on Immunogenicity Assessment for Therapeutic Protein Products1 and
Comparability exercises are commonly required at certain milestones during drug development as well as after product registration when changes are implemented into the manufacturing process. The goal is to evaluate if the product remains highly similar (not necessarily identical) before and after the change in terms of quality and stability and have no adverse impact on safety and efficacy predicted for the patients. This assessment requires product-specific knowledge gathered through drug development, taking a totality-of-evidence approach. The different levels of information are obtained from analytical studies for characterization of the molecule, animal studies for toxicity, pharmacokinetics and pharmacodynamics for pharmacological activities, and clinical studies for safety/tolerability, immunogenicity and efficacy. This Webinar discusses strategies and considerations for analytical characterization of protein structure and function which forms the foundation of the comparability demonstration.
Single-Use Process Analytical Technologies (PAT) tools have a great potential to not only increase process understanding at the seed stage but also simplify cell culture operations. By utilizing PAT, the risk from bioburden or contamination can be significantly reduced and the overall operating efficiency increased. In fact, PAT also provides a data-driven platform to integrate Process Development and Manufacturing Operations that can mitigate risks associated with technology/process transfer.